Sexual Dysfunction in Women
On this page
Direct answer
Female sexual dysfunction is a persistent disturbance in one or more of desire, arousal, orgasm or pain that causes personal distress, and in women these domains overlap far more than they do in men — DSM-5 merges hypoactive desire and arousal problems into female sexual interest/arousal disorder for exactly that reason. Diagnosis requires the problem to be present for about six months and to cause distress, because low frequency alone is not pathology. Causes are biopsychosocial: oestrogen deficiency and lactational hyperprolactinaemia, depression and its SSRI treatment, thyroid disease, diabetes, antihypertensives, relationship conflict, past trauma and cultural conditioning all feed the same presentation. Management follows the PLISSIT ladder (Permission, Limited information, Specific suggestions, Intensive therapy) — most cases resolve in the first three rungs with education, lubricants, topical oestrogen and guided changes, reserving psychosexual therapy and the few pharmacological options for refractory cases.
What you must remember
- Classification to quote: desire/arousal disorder (merged in DSM-5), orgasmic disorder, genito-pelvic pain/penetration disorder (which unifies dyspareunia and vaginismus), and substance- or medication-induced dysfunction.
- Diagnostic gate: symptoms of roughly six months' duration plus clinically significant personal distress; distress is what separates dysfunction from preference.
- Hormonal drivers: menopausal and postpartum oestrogen deficiency causing atrophy and dryness; lactational hyperprolactinaemia suppressing desire; combined contraceptives occasionally reducing free testosterone and libido.
- Drug offenders: SSRIs (delayed orgasm, reduced desire — the commonest iatrogenic cause), beta blockers, thiazides, antipsychotics, corticosteroids; address by dose change, drug holiday or substitution where feasible.
- Systemic screen: depression, diabetes, hypothyroidism, anaemia, chronic renal or liver disease — and a medication and contraception review in every patient before labelling the problem psychological.
- PLISSIT model: Permission (validate that sexual concerns are legitimate), Limited information (anatomy, the sexual response cycle), Specific suggestions (lubricants, positioning, sensate focus exercises), Intensive therapy (referral for psychosexual or couples therapy).
- Pharmacology is narrow: transdermal testosterone is used off-label mainly in post-hysterectomy postmenopausal women where regulated; flibanserin (daily) and bremelanotide (on-demand injection) are approved for premenopausal hypoactive desire disorder in some countries but are not standard of care in Indian practice; vaginal oestrogen and lubricants are the workhorses.
- Red flags: sudden dyspareunia with postcoital bleeding mandates pelvic examination and cervical screening before any psychological label.
A worked consultation
A 34-year-old presents with "no interest" for a year, since her second delivery; she is breastfeeding, on no medication, and reports dryness and pain at entry leading to avoidance. The diagnostic mistake is to reach for a desire drug; the correct sequence is biological first — lactational hypo-oestrogenism explains the dryness, the dryness explains the pain, and the pain explains the avoidance and apparent desire loss. Treatment runs the PLISSIT ladder: permission to discuss sexuality openly, information that this is physiological and reversible, specific suggestions of a silicone lubricant plus vaginal moisturisers (and topical oestrogen if needed), scheduled couple time while breastfeeding continues, and pelvic floor physiotherapy for secondary guarding. Review at three months resolves most of it. Contrast a 42-year-old on paroxetine for depression with anorgasmia: her pathway involves the treating psychiatrist — dose reduction, switching to bupropion-augmented or mirtazapine-based regimens — because no lubricant fixes SSRI-induced orgasmic delay. Both cases illustrate the exam's central teaching: the domain affected, its duration, and its distress define the disorder, while the cause decides the treatment rung.
Where students slip
Candidates import the male model — assume desire precedes arousal in women, whereas in responsive desire, arousal often precedes and generates desire, a distinction with real therapeutic consequences. The second slip is treating low desire as pathological without the distress criterion: a woman content with infrequent intercourse has no disorder. Third, the reflex to psychological causation without excluding anaemia, hypothyroidism, diabetes, depression and SSRIs in the Indian clinic, where these are highly prevalent. Finally, pharmacology overreach: sildenafil has no established role in female dysfunction (evidence largely negative except narrow subgroups), and quoting it as treatment costs marks; flibanserin exists but with hypotension and interactions, and it is not part of routine Indian management.
Frequently asked questions
How is female sexual dysfunction classified?
Into desire/arousal disorder (merged in DSM-5), orgasmic disorder and genito-pelvic pain/penetration disorder, each requiring roughly six months of symptoms with personal distress.
What is the PLISSIT model?
A stepped counselling framework — Permission, Limited information, Specific suggestions, Intensive therapy — used to escalate management of sexual dysfunction from validation to specialist psychosexual therapy.
Which drugs commonly cause sexual dysfunction in women?
SSRIs top the list (reduced desire and delayed orgasm), along with beta blockers, thiazides, antipsychotics and hormonal contraceptives in some women.
Why does desire fall during lactation?
High prolactin and low oestrogen suppress libido and produce vaginal dryness, making arousal and comfortable intercourse difficult — a physiological, reversible state.
Is there any approved drug for hypoactive sexual desire disorder?
Flibanserin and bremelanotide are approved for premenopausal women in some countries; transdermal testosterone is used off-label in selected postmenopausal women — none is routine practice in India, where lubricants, topical oestrogen and counselling remain first-line.